Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 61.2% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 48,705 shares of the biopharmaceutical company’s stock after acquiring an additional 18,490 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Alnylam Pharmaceuticals were worth $16,115,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ALNY. Capital Research Global Investors boosted its holdings in shares of Alnylam Pharmaceuticals by 0.4% in the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock worth $3,293,516,000 after buying an additional 31,184 shares during the period. Groupama Asset Managment lifted its holdings in shares of Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after buying an additional 2,483,697 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 6.1% in the 4th quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock valued at $1,056,884,000 after buying an additional 151,480 shares in the last quarter. Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $895,816,000. Finally, Orbis Allan Gray Ltd increased its holdings in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insiders Place Their Bets

In other news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $312.78 on Friday. The business has a 50 day simple moving average of $295.50 and a 200 day simple moving average of $328.31. The stock has a market cap of $41.76 billion, a price-to-earnings ratio of 85.46 and a beta of 0.27. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. Alnylam Pharmaceuticals, Inc. has a 52-week low of $273.11 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the business earned ($0.44) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 96.4% on a year-over-year basis. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Truist Financial lowered their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Jefferies Financial Group reaffirmed a “hold” rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Wells Fargo & Company lifted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Finally, Chardan Capital restated a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $461.39.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.